



## ASX ANNOUNCEMENT

### **Lumos Secures Distribution for FebriDx® in the Baltic Region**

**MELBOURNE, Australia (18 December 2025)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has executed a new distribution agreement with the Interlux Group (“Interlux”) for the sale of FebriDx® across the Baltic region, covering Lithuania, Estonia and Latvia.

Incorporated in 1994, Interlux is a well-established medical distributor operating across Lithuania, Estonia and Latvia. Supported by a team of more than 100 sales specialists, the company services over 1,000 customers throughout the Baltic region. Interlux has a strong track record in supplying diagnostic products and healthcare technologies to laboratories, hospitals, clinics and primary care providers.

Under the new agreement, Interlux will oversee the sales, distribution and inventory management of FebriDx® throughout the Baltic region. Interlux has placed an initial stocking order to support immediate availability of FebriDx® for customers across the three markets. The agreement will enable Interlux to distribute FebriDx® into primary care, urgent care and outpatient settings across the Baltics, supported by its established regional logistics and customer relationships.

Lumos continues to build a broad European distribution network for FebriDx®, with existing agreements already in place through Henry Schein across multiple geographies, including the UK, Spain, Portugal and the Netherlands. The addition of Interlux strengthens this footprint and further supports Lumos’ strategy of expanding access to FebriDx® through experienced regional distribution partners in Europe.

Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics said: *“We are pleased to partner with Interlux as we continue expanding FebriDx® into international markets. Their strong regional presence and deep customer relationships make them an excellent partner to accelerate adoption across the Baltic region.”*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

## About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

## Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

## Media Contacts:

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

## Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 409 392 687

## Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598